PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Neurobehavioral manifestation

Drugs in development · updated 30 October 2026

Neurobehavioral manifestation: drugs in development

As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for neurobehavioral manifestation. 3 are experimental, that is not yet approved in the United States.

6Active trials
3Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
GNR-055II–III1NCT05208281
NGN-401III1NCT05898620
CTH120II1NCT07654114

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
BaricitinibOlumiant®II1NCT07608796
GuanfacineIntuniv®, Tenex®II1NCT06408246
SertralineZoloft®II1NCT06408246
ModafinilProvigil®Early I1NCT01988883
PropranololHemangeol®, Innopran Xl®Early I1NCT01988883

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D019954 “Neurobehavioral Manifestations”.

ItalianoFrançaisDeutsch